FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesCarol Jarvis – European Knowledge Forum Patient Testimonial 2022
Topic: Conference
Video
Members
Preparing for the Post-Brexit Clinical Supply Chain
Topics: Pharma Industry, Regulatory
Position Paper
Free
FDA Policy for REMS Reqmts during COVID-19
Topics: Health Care, Pharma Industry, Strategic Planning
Guidance Document
Free
